STAT3 and breast cancer: Moreover, the unique capacity of rucaparib to inhibit STAT3 phosphorylation in MDA-MD-231 and MDA-MB-468 human breast cancer cell lines has been previously reported at concentrations below 2.5 μM, but this was not observed in response to olaparib25.